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Abstract
 
Upon viral stimulation, the natural interferon (IFN)-
 
a
 
/
 
b
 
–producing cells (IPCs; also known as
pre-dendritic cells (DCs [2]) in human blood and peripheral lymphoid tissues rapidly produce
huge amounts of IFN-
 
a
 
/
 
b
 
. After performing this innate antiviral immune response, IPCs can
differentiate into DCs and strongly stimulate T cell–mediated adaptive immune responses. Us-
ing four-color immunofluorescence flow cytometry, we have mapped the developmental path-
way of pre-DC2/IPCs from CD34
 
1
 
 hematopoietic stem cells in human fetal liver, bone mar-
row, and cord blood. At least four developmental stages were identified, including
CD34
 
11
 
CD45RA
 
2
 
 early progenitor cells, CD34
 
11
 
CD45RA
 
1
 
 late progenitor cells,
CD34
 
1
 
CD45RA
 
11
 
CD4
 
1
 
interleukin (IL)-3R
 
a
 
11
 
 pro-DC2, and CD34
 
2
 
CD45RA
 
11
 
CD4
 
1
 
IL-3R
 
a
 
11
 
 pre-DC2/IPCs. Pro-DC2s have already acquired the capacity to produce
large amounts of IFN-
 
a
 
/
 
b
 
 upon viral stimulation and to differentiate into DCs in culture with
IL-3 and CD40 ligand. CD34
 
11
 
CD45RA
 
2
 
 early progenitor cells did not have the capacity to
produce large amounts of IFN-
 
a
 
/
 
b
 
 in response to viral stimulation; however, they can be in-
duced to undergo proliferation and differentiation into IPCs/pre-DC2 in culture with FLT3
ligand.
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Introduction
 
Dendritic cells (DCs)
 
1
 
 represent heterogeneous populations
of hematopoietic-derived cells that display potent ability to
induce primary T cell activation, polarization, and in cer-
tain circumstances, tolerance (1–4). The distinct capacity of
DCs to induce immunity versus tolerance or Th1 versus
Th2 responses depends on their maturation stage (2, 5), sig-
nals that induce or inhibit DC maturation (2, 5, 6), as well
as the lineage origin of DCs (7–12). A lymphoid DC devel-
opmental pathway was suggested by the finding that mouse
thymic lymphoid precursors can give rise to both T cells
and CD8
 
1
 
CD11b
 
2
 
 DCs (13, 14). In addition, a well-estab-
lished myeloid DC pathway giving rise to CD8
 
2
 
CD11b
 
1
 
DCs has been defined (15–17). Recent studies suggest that
CD8
 
1
 
CD11b
 
2
 
 lymphoid DCs and CD8
 
2
 
CD11b
 
1
 
 my-
eloid DCs may have different functions in T cell activation/
tolerance or Th1/Th2 differentiation (7, 9, 18–24).
In humans, two distinct populations of DC precursors
exist in the blood. Monocytes (pre-DC1), which belong to
the myeloid lineage, differentiate into immature DC1 after
5 d of culture in GM-CSF and IL-4 (25, 26). Upon CD40
ligand activation, immature myeloid DC1 undergo matura-
tion and produce large amounts of IL-12 (27, 28). The ma-
ture DC1 induced by CD40 ligand are able to polarize na-
ive CD4
 
1
 
 T cells into Th1 cells (29). The second type of
DC precursor cells, pre-DC2 (previously known as plasma-
cytoid T/monocytes) are characterized by a unique surface
phenotype (CD4
 
1
 
IL-3R
 
a
 
11
 
CD45RA
 
1
 
HLA-DR
 
1
 
 lin-
eage marker-negative and CD11c
 
2
 
), and at the ultrastruc-
tural level resemble Ig-secreting plasma cells (30, 31). Sev-
eral lines of evidence suggest that pre-DC2s are of
lymphoid origin: (a) pre-DC2 lack expression of the my-
eloid antigens CD11c, CD13, CD33, and mannose receptor
(30, 32), (b) pre-DC2 isolated from the thymus express the
lymphoid markers CD2, CD5, and CD7 (32), (c) pre-DC2
have little phagocytic activity (30), (d) pre-DC2 do not dif-
ferentiate into macrophages after culture with GM-CSF
 
Address correspondence to Yong-Jun Liu, Department of Immunobiol-
ogy, DNAX Research Institute of Molecular and Cellular Biology, 901
California Ave., Palo Alto, CA 94304. Phone: 650-496-1157; Fax: 650-
496-1200; E-mail: yliu@dnax.org
 
1
 
Abbreviations used in this paper:
 
 APC, allophycocyanin; DC, dendritic
cell; FSC, forward scatter; HS, human serum; IPC, natural type 1 inter-
feron-producing cell; LC, Langerhans cell; MNC, mononuclear cell;
SCF, stem cell factor; SSC, side scatter. 
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and M-CSF (30), (e) pre-DC2 express pre–TCR-
 
a
 
 tran-
scripts (32, 33), and (f) development of pre-DC2, T and B
cells, but not myeloid DCs is blocked by ectopic expression
of inhibitor of DNA binding (Id)2 or Id3, as shown by
Spits et al., in this issue (34). Pre-DC2 differentiate into
immature DC2 when cultured with monocyte conditional
medium (35), IL-3 (29, 30, 36), IFN-
 
a
 
/
 
b
 
, and TNF-
 
a
 
, or
viruses like herpes simplex virus or influenza virus (37).
Upon CD40 ligand activation, immature DC2 undergo
maturation (30), but produce only low levels of IL-12 (29).
Mature DC2 are able to polarize naive CD4
 
1
 
 T cells into a
Th2 phenotype (10, 29). Recent studies showed that the
pre-DC2 are the elusive natural IFN-producing cells
(IPCs), capable of producing high amounts of IFN-
 
a
 
/
 
b
 
upon viral stimulation (38, 39). Taken together, pre-DC2/
IPCs represent a unique hematopoietic lineage, capable of
performing crucial functions both in innate and in adapted
immunity.
The pathway underlying the development of pre-DC2/
IPCs from CD34
 
1
 
 hematopoietic stem cells has not been
elucidated. Caux et al. (40) showed that cord blood
CD34
 
1
 
 hematopoietic progenitor cells cultured in GM-
CSF, stem cell factor (SCF), and TNF-
 
a
 
 differentiate along
two DC pathways: (a) the Langerhans cell (LC) pathway, in
which intermediate CD14
 
2
 
CD1a
 
1
 
 DC precursors differ-
entiated into LCs characterized by the expression of CD1a,
Birbeck granules, the Lag antigen, and E cadherin; and
(b) the dermal DC pathway, in which intermediate
CD14
 
1
 
CD1a
 
2
 
 DC precursors differentiate into dermal
DCs characterized by the expression of CD1a, CD9,
CD68, CD2, and factor XIIIa (41). Recently, a common
human lymphoid progenitor in the bone marrow was de-
scribed that expresses both CD45RA and CD10 (42).
These cells develop into T, B, NK cells, and DCs, but not
into erythroid, megakaryocytic, and myeloid cells. In these
experiments, exclusively CD1a
 
1
 
 LCs were generated with
a cocktail of nine cytokines (IL-1, IL-3, IL-6, IL-7, SCF,
GM-CSF, TNF, erythropoietin, and FLT3 ligand). Of
these cytokines, the hematopoietic growth factor FLT3
ligand has been shown to play an important role in the pro-
liferation, survival, and differentiation of early murine and
human hematopoietic precursor cells (43, 44). Interest-
ingly, volunteer donors injected with FLT3 ligand had a
13-fold increase in pre-DC2 number and a 48-fold increase
in CD11c
 
1
 
 myeloid DC number in the blood stream (45).
Consistent with this finding, injection of mice with human
FLT3 ligand led to dramatically increased numbers of both
myeloid and lymphoid DCs not only in the peripheral
blood, but also in the bone marrow, thymus, and secondary
lymphoid tissues (7, 9, 46, 47). Two recent reports revealed
a five- to sixfold increase in pre-DC2/IPC numbers in the
blood of G-CSF–treated donors (10, 45). However, it is
not clear from these studies whether FLT3 ligand and
G-CSF enhance the differentiation of pre-DC2 from he-
matopoietic progenitor cells or promote the migration of
pre-DC2 from bone marrow into blood.
The aims of this study are: (a) to trace the developmental
pathway of pre-DC2/IPCs from CD34
 
11
 
 hematopoietic
progenitor cells, and (b) to identify the stimuli that can in-
duce CD34
 
11
 
 hematopoietic progenitor cells to differenti-
ate into pre-DC2/IPCs.
In this paper, we describe the identification of CD34-
expressing precursors of pre-DC2/IPCs from human fetal
tissues and cord blood. In addition, we report on the gen-
eration of pre-DC2/IPCs from early hematopoietic stem
cells in in vitro cultures.
 
Materials and Methods
 
Flow Cytometric Analysis and Cell Sorting of Human Cord Blood
and Fetal Tissues.
 
Fetal tissue (16–22 wk of gestation) and cord
blood were obtained from Advanced Bioscience Resources Inc.
Mononuclear cells (MNCs) were isolated from these samples by
Ficoll density gradient centrifugation (1.077 g/ml Lymphoprep;
Amersham Pharmacia Biotech). MNCs were washed three times
in PBS (BioWhittaker), and resuspended in PBS containing 2%
(vol/vol) human serum (HS; Gemini Bioproducts) and 2 mM
EDTA (PBS/HS/EDTA). Magnetic bead depletion was per-
formed to remove lineage-positive cells. In brief, MNCs were in-
cubated with a mixture of antibodies against CD3 (OKT-3 as-
cites), CD8 (OKT-8 ascites), CD14 (RPA-M1 ascites), CD16
(3G8; Immunotech), CD19 (4G7 ascites), CD56 (My31 ascites),
CD66B (80H3; all from Immunotech), and glycophorin A
(10F7MN ascites). After two washes, the cells were incubated
with goat anti–mouse IgG coupled to magnetic beads (Dyna-
beads
 
®
 
 M-450, goat anti–mouse IgG; Dynal) and isolated accord-
ing to the manufacturer’s instructions. The enriched cells were
stained either to perform a four-color flow cytometric analysis or
to purify different subsets by cell sorting (FACS
 
®
 
; Becton Dickin-
son). Cells were incubated with a cocktail of the following FITC-
conjugated antibodies: CD3 (Leu-4), CD14 (Leu-M3), CD15
(Leu-M1), CD16 (Leu-11a), CD20 (Leu-16), CD57 (Leu-7; all
from Becton Dickinson), and CD11c (3.9; Caltag Laboratories).
To analyze expression of different antigens on the lineage FITC-
negative cells, the cells were stained with CD34-allophycocyanin
(APC; HPCA-2; Becton Dickinson) and CD45RA-Tricolor
(MEM 56; Caltag), and in addition, different PE-conjugated anti-
bodies: anti–HLA-DR (Becton Dickinson), CD4 (Leu-3a; Bec-
ton Dickinson), and IL-3R
 
a
 
 (9F5l; BD PharMingen). For cell
sorting, the enriched cells were stained with CD34-APC
(HPCA-2), CD45RA-PE (Leu-18), and CD4-biotin (Leu-3a), all
from Becton Dickinson. Expression of CD4 was revealed after a
second step staining using the streptavidin-alexa594 (Molecular
Probes) or avidin–Texas red (BD PharMingen) conjugate.
 
DC2 Culture Conditions.
 
For generation of DC2, sorted cells
were cultured for 5 d in the presence of IL-3 (10 ng/ml; R&D
Systems) and CD40 ligand–transfected L cells (10,000/well, irra-
diated at 7,000 rads) in 25 
 
m
 
l Yssel’s medium (48) containing 2%
HS in microwell plates (Robbins Scientific Corporation).
 
Proliferation Assay.
 
Sorted cells (15,000/well) were cultured
in duplicate for the indicated durations in the presence of IL-3
(10 ng/ml; R&D Systems), GM-CSF (800 U/ml; a gift from
Schering-Plough, Kenilworth, NJ), FLT3 ligand (100 ng/ml; a
gift from S. Menon, DNAX Research Insitute of Molecular and
Cellular Biology), and SCF (10 ng/ml; R&D Systems) in 200 
 
m
 
l
Yssel’s medium (48) containing 2% HS in 96-well round-bot-
tomed culture plates (Falcon
 
®
 
; Becton Dickinson). [
 
3
 
H]Thymi-
dine (1 
 
m
 
Ci/well; Amersham Pharmacia Biotech) was added dur-
ing the last 8 h of the culture. Proliferation data were calculated
in counts per minute. 
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IFN-
 
a
 
 Production.
 
Cells (10
 
6
 
/ml) were cultured in 25 
 
m
 
l Ys-
sel’s medium (48) containing 2% HS in microwell
 
 
 
plates (Rob-
bins Scientific). HSV-1, KOS strain, attenuated by 
 
g
 
 irradiation
(a gift from R. Chase, Schering-Plough, Kenilworth, NJ) was
added at 10 PFU/cell. After 24 h, supernatants were collected
and frozen at 
 
2
 
20
 
8
 
C before analysis by an IFN-
 
a
 
–specific sand-
wich ELISA (Biosource International). Appropriate dilutions of
the supernatants were made if necessary.
 
Pre-DC2/IPC Generation from Stem Cells.
 
Sorted cells
(25,000–50,000/well) were cultured in 200 
 
m
 
l Yssel’s medium
containing 2% HS in 96-well round-bottomed culture plates.
Cytokines were added at the following concentrations: FLT3
ligand (100 ng/ml; provided by S. Menon, DNAX Research In-
stitute of Molecular and Cellular Biology), GM-CSF (800 U/ml;
a gift from Schering-Plough), SCF (10 ng/ml; R&D Systems),
IL-3 (10 ng/ml; R&D Systems), IL-7 (10 ng/ml; R&D Systems),
and G-CSF (5 ng/ml; R&D Systems). Cell cultures were re-
freshed every 5 d by demi-depletion and splitted if necessary.
 
Results
 
Identification of Pro-DC2, the CD34-expressing Immediate
Precursors of Pre-DC2/IPCs.
 
Pre-DC2/IPCs have been
identified in tonsil, adult peripheral blood (29, 30), and
postnatal thymus (32). To define the developmental path-
way of pre-DC2/IPCs from CD34
 
11
 
 hematopoietic pro-
genitors, lineage-positive cells (including T, B, and NK
cells, and monocytes, granulocytes, and erythrocytes) from
fetal liver, bone marrow, cord blood, and adult blood were
depleted using magnetic beads. The remaining lineage-
negative cells were analyzed by four-color flow cytometry
analysis after staining with: (a) FITC-conjugated antibodies
against lineage markers (CD3, CD11c, CD14, CD15,
CD16, CD20, and CD57), in order to exclude the remain-
ing lineage-positive cells; (b) anti-CD34 antibody conju-
gated to APC, to follow the populations of hematopoietic
progenitor cells; (c) anti-CD45RA antibody conjugated to
Tricolor as a positive marker to identify pre-DC2/IPCs
and to distinguish CD34
 
11
 
CD45RA
 
2
 
 early progenitors
from CD34
 
11
 
CD45RA
 
1
 
 late progenitors; and (d) various
PE-conjugated antibodies known to detect antigens ex-
pressed on pre-DC2/IPCs, such as CD4 and IL-3R
 
a
 
. Af-
 
ter gating on FITC-negative cells, four populations of cells
(A, B, C, and D) were identified (Fig. 1). CD34
 
11
 
CD45RA
 
2
 
 cells (population A) are enriched for early mul-
tipotent progenitor cells (49), whereas CD34
 
11
 
CD45RA
 
1
 
cells (population B) are enriched for myeloid/lymphoid
progenitors, which have lost the potential to develop into
the erythroid lineage (42). These two populations of
CD34
 
11
 
 progenitor cells expressed lower levels of CD4
and IL-3R
 
a
 
 than expressed by pre-DC2/IPCs derived
from adult peripheral blood (Fig. 2) or tonsils (data not
shown). A substantial proportion of CD34
 
1
 
CD45RA
 
1
 
cells in population C and CD34
 
2
 
CD45RA
 
1
 
 cells in popu-
lation D expressed a moderate level of CD4 and a high
level of IL-3R
 
a
 
, similar to the expression level detected on
pre-DC2/IPCs from adult peripheral blood (Fig. 2) or ton-
sils (data not shown). The CD4
 
2
 
 and IL-3R
 
a
 
2
 
 fraction of
cells in populations C and D expressed NKRP1A (data not
shown), and most likely represent cells of the NK lineage
(50). Thus, according to these phenotypical analyses, the
CD34
 
2
 
CD45RA
 
1
 
CD4
 
1
 
IL-3R
 
a
 
11
 
 cells in population D
may represent pre-DC2/IPCs. Furthermore, because of the
low CD34 expression, the CD34
 
1
 
CD45RA
 
1
 
CD4
 
1
 
IL-3R
 
a
 
11
 
 cells in population C may represent the im-
mediate progenitors of pre-DC2/IPCs. Accordingly, the
CD34
 
1
 
CD45RA
 
1
 
CD41IL-3Ra11 cells in population C
will be referred to as pro-DC2 (for progenitor of pre-
DC2). Both pre-DC2 in fraction D and pro-DC2 in frac-
tion C display a similar size profile (intermediate size be-
tween lymphocytes and monocytes) revealed by forward
scatter (FSC)/side scatter (SSC) (Fig. 2) and a plasmacytoid
morphology by Giemsa staining (not shown). The presence
of pro-DC2 could be detected in cord blood, fetal bone
marrow, fetal liver, and at very low numbers in peripheral
blood, but not in fetal thymus (Fig. 1). All tissues analyzed
contained pre-DC2 in population D (Fig. 1 and data not
shown).
Pro-DC2 and Pre-DC2 Produce Large Amounts of IFN-a
after Viral Stimulation. A key function feature of pre-
DC2/IPCs is the rapid production of huge amounts of
IFN-a/b in response to viral stimulation. (37, 38). To
determine if CD341 pro-DC2s in population C have ac-
Figure 1. Expression of CD34
and CD45RA on lineage-nega-
tive cells reveals four different
subpopulations in human fetal
liver, fetal bone marrow, fetal
thymus, cord blood, and adult
peripheral blood samples. Lin-
eage-positive cells (including T,
B, and NK cells, and monocytes,
granulocytes, and erythrocytes)
were depleted using magnetic
beads. The enriched cells were
analyzed by four-color flow cy-
tometric analysis after staining
with an FITC-conjugated cocktail of antibodies against lineage markers (including CD3, CD11c, CD14, CD15, CD16, CD20, and CD57), anti-CD34–
APC, anti-CD45RA–Tricolor, and the PE-conjugated antibodies anti-CD4 and anti–IL-3Ra. After electronic gating on FITC-negative cells, four pop-
ulations of cells (A, B, C, and D) were identified: population A, CD3411CD45RA2; population B, CD3411CD45RA1; population C,
CD341CD45RA1; and population D, CD342CD45RA1.1788 Generation of IPCs from Stem Cells
quired this function, pro-DC2 were stimulated with irradi-
ated HSV-1 (10 PFU/cell) for 24 h, in parallel with pre-
DC2 and CD3411 progenitor cell populations A and B.
CD3411CD45RA2 (population A) isolated from either
cord blood or fetal liver only produced low levels of IFN-a
(population A, ,17–111 pg/ml, n 5 11; Table I). Similar
low IFN-a levels were found for virally stimulated cord
blood CD3411CD45RA1 (population B) cells (population
B, 17–48 pg/ml, n 5 4). However, the range of IFN-a
production from fetal liver–derived CD3411CD45RA1
cells was more variable (population B, ,17–4,257 pg/ml,
n 5 11). Pro-DC2 in population C and pre-DC2 in popu-
lation D isolated from either cord blood or fetal liver pro-
duced huge amounts of IFN-a (pro-DC2, 172–90,464 pg/
ml, n 5 10; pre-DC2, 1,024–15,830 pg/ml, n 5 8; Table
I). No IFN-a was detectable from the CD42 cells in popu-
lation D after purification and viral stimulation, suggesting
that these cells are different from the pre-DC2 (data not
shown).
These data indicate that pre-DC2s from fetal liver and
cord blood are similar to pre-DC2/IPCs isolated from
adult blood and tonsils regarding their surface phenotype
and function in antiviral innate immunity. Furthermore, al-
though pro-DC2 express the CD34 antigen, these cells al-
ready acquired the functional capacity to produce a large
amount of IFN-a in response to viral stimulation, and
therefore pro-DC2 may represent the earliest IPCs during
hematopoiesis. In addition, the ability to rapidly produce
vast amounts of type 1 IFN is acquired during hematopoi-
etic development, as CD3411 early hematopoietic progen-
itors only produced a low amount of IFN-a in response to
viral stimulation.
Pro-DC2s Differentiate into Mature DCs upon IL-3 and
CD40 Ligand Stimulation.  Adult blood and tonsil-derived
pre-DC2 depend on IL-3 for their survival (30). Culture of
pre-DC2 with IL-3– and CD40 ligand–transfected L cells
results in their differentiation into mature DCs (DC2 [29,
30]). To determine whether pro-DC2 have the potential to
Figure 2. Phenotype of popu-
lations A–D. Cells in populations
A–D of human fetal liver shown
in Fig. 1 were electronically
gated and analyzed for the FSC/
SSC size profiles and the expres-
sion of CD4 and IL-3Ra. The
black dots on the FSC/SSC pro-
file represent the IL-3Ra11
fraction. The gray dots represent
IL-3Ralow lymphocyte fraction.
Open histograms represent ex-
pression after staining with an
isotype control antibody, and the
shaded histograms represent ex-
pression of CD4 or IL-3Ra on
populations A–D. The pheno-
type of populations A–D from
human adult blood, bone mar-
row, and cord blood were simi-
lar to that of fetal liver.1789 Blom et al.
differentiate into mature DCs, the cells were cultured for
5 d with IL-3 and CD40 ligand in parallel with pre-DC2s.
After 5 d of culture, both pro-DC2 and pre-DC2 acquired
mature DC morphology (data not shown). Moreover, flow
cytometry analysis revealed that both cultured pro-DC2
and pre-DC2 expressed mature DC markers, such as high
HLA-DR, CD80, CD86, CD40, and CD83 (Fig. 3).
These mature DC2 strongly induced the proliferation of al-
logeneic naive CD41 T cells (data not shown). These re-
sults suggest that pro-DC2 and pre-DC2 have an equal po-
tential to develop into mature DCs.
Pro-DC2 Have a Limited Proliferative Capacity. The pro-
liferation potential of pro-DC2 in response to hemato-
poietic cytokines was analyzed, in parallel with that of
pre-DC2, CD3411CD45RA2 (population A), and
CD3411CD45RA1 (population B) from fetal liver. Cells
of each population were cultured for a total of 5 d in a cy-
tokine cocktail consisting of GM-CSF, IL-3, SCF, and
FLT3 ligand. [3H]Thymidine was added to the cultures 8 h
before incorporation was analyzed. Pro-DC2 proliferated
moderately better than pre-DC2 (Fig. 4 A), but 50–100
times less than CD3411CD45RA2 (population A) and
CD341CD45RA1 (population B; Fig. 4 B). In addition,
both pro-DC2 and pre-DC2 failed to increase cell numbers
in these cultures (data not shown).
These data suggest that although pro-DC2 still express
the CD34 antigen and proliferate moderately better in re-
sponse to cytokines than pre-DC2, the pro-DC2 may have
lost the expansion potential of hematopoietic progenitor
cells.
FLT3 Ligand Induces CD3411CD45RA2 Early Hemato-
poietic Progenitor Cells to Differentiate into IFN-a–producing
Cells. CD3411CD45RA2 cells did not produce IFN-a
after viral stimulation, but were found to have the best
Table I. IFN-a–producing Capacity of Purified Pro-DC2, Pre-DC2, and CD3411 Progenitor Subsets from Cord Blood and Fetal Liver
CD3411CD45RA2 CD3411CD45RA1 Pro-DC2 Pre-DC2
pg/ml pg/ml pg/ml pg/ml
Cord blood
1 32 (610) 36 (65) 4,295 (669) 3,254 (655)
2 41 (63) 48 (63) 172 (66) 1,024 (67)
3 43 (620) 43 (65) 6,938 (667) 13,020 (6322)
4 22 1,284 (643) 3,484 (6333)
5 22 10,835 (6780) 9,241 (6712)
6 20 (61) 17 (65) 22
Fetal liver
1 ,17 1,270 (6150) 90,464 (61391) 2
2 76 (66) 1,241 (622) 39,577 (6678) 15,830 (61,121)
3 111 (69) 41 (637) 20,308 (6714) 900 (648)
4 81 (632) 1,496 (641) 20,308 (6714) 900 (648)
5 32 (63) 4,257 (695) 90,010 (6856) 2
6 23 (63) 46 (69) 22
7 ,17 ,17 22
CD3411 progenitor subsets, pro-DC2, and pre-DC2 were purified by flow cytometric cell sorting and stimulated with HSV-1 for 24 h. The amount
of IFN (pg/ml) produced in the supernatants was measured by ELISA. The detection limit of the ELISA was 17 pg/ml. Numbers in parentheses
represent standard deviations. 2, not tested.
Figure 3. Flow cytometric
analysis of pro-DC2 and pre-
DC2 after 5 d of culture with
IL-3 and CD40 ligand L cells.
Harvested cells were stained us-
ing PE-conjugated antibodies
against HLA-DR, IL-3Ra,
CD80, CD86, CD40, and
CD83. Open histograms repre-
sent expression after staining
with an isotype control anti-
body. The shaded histograms
represent expression of the indi-
cated antigen.1790 Generation of IPCs from Stem Cells
clonal expansion potential (Fig. 4 B). We investigated
whether CD3411CD45RA2 early progenitor cells can be
induced to differentiate into pre-DC2/IPCs in vitro with
one of the following cytokines: IL-3, IL-7, SCF, FLT3
ligand, GM-CSF, or G-CSF. After 11 and 25 d of culture,
20,000 cells were stimulated with HSV-1 for 24 h and the
amount of IFN-a secreted in the supernatants was analyzed
by ELISA. At day 11, cells cultured with FLT3 ligand or
SCF produced moderate levels of IFN-a (FLT3 ligand,
3,323 pg/ml; SCF, 2,910 pg/ml; Fig. 5) after viral stimula-
tion. Cells cultured in any of the other cytokines produced
low to undetectable levels of IFN-a (,17–24 pg/ml). The
cells expanded in number up to 35-fold with IL-3 and 24-
fold with GM-CSF, whereas the cell number expansion
with the other cytokines was ,5-fold (data not shown).
Strikingly, after 25 d of culture with FLT3 ligand,
CD3411CD45RA2 cells produced 15,794 pg/ml of IFN-a
after viral stimulation (Fig. 5). Interestingly, the capacity of
cells to produce IFN-a after culture in SCF had decreased
to 767 pg/ml (Fig. 5). Cellular expansion in this experi-
ment was 24-fold in FLT3 ligand and 6-fold in SCF (data
not shown). None of the other cytokines had induced the
CD341CD45RA2 cells to produce IFN-a upon viral chal-
lenge (Fig. 5).
To analyze the detailed kinetics of the capacity of FLT3
ligand–cultured cells to produce IFN-a in response to
HSV-1 stimulation, CD3411CD45RA2 fetal liver cells
were cultured in FLT3 ligand and harvested every 5 d. Af-
ter 10–15 d of culture, CD3411CD45RA2 early progeni-
tor cells acquired the capacity to produce significant
amounts of IFN-a (3,000–5,000 pg/ml; Fig. 6 A). This ca-
pacity was further increased at day 21 (20,000 pg/ml),
peaked at days 25 to 30 (.58,000 pg/ml), and started to
decrease after 50 d of culture. The cell number of
CD3411CD45RA2 cells cultured in FLT3 ligand in this
experiment increased six- to sevenfold after 4 wk of culture
(data not shown).
FLT3 Ligand Induces CD3411CD45RA2 Early Progenitor
Cells to Differentiate into CD41HLA-DR1IL-3Ra11
CD45RA1CD11c2 Pre-DC2. Next, we used four-color
flow cytometry to determine whether the production of
the vast amounts of IFN-a by FLT3 ligand–cultured cells
was due to the generation of pre-DC2/IPCs. In normal hu-
man adult blood, the frequency of CD41HLA-DR1IL-
3Ra11CD45RA1CD11c2 pre-DC2s is between 0.3 and
0.8% of total peripheral blood MNCs (30). The percentage
of CD41HLA-DR1IL-3Ra11CD45RA1CD11c2 cells in
freshly isolated CD3411CD45RA2 early progenitor cells
from fetal liver or in 5 d FLT3 ligand–cultured cells was
,0.05% (Fig. 1 B and Fig. 6, B and C). A progressive in-
crease (from 1.5 to 6%) in the percentage of HLA-DR1IL-
3Ra11 cells was observed from days 11 to 20 of culture
(Fig. 6, B and C). Between days 25 and 30, up to 10%
of the cultured cells were HLA-DR1IL-3Ra11 cells
(Fig. 6, B and C). Detailed flow cytometric analysis of
CD3411CD45RA2 cells at day 30 of FLT3 ligand culture
revealed that the HLA-DR1IL-3Ra11 cells expressed
CD4, CD45RA, and low levels of CD11c (Fig. 7 A), a typ-
ical phenotype of pre-DC2/IPCs. Most interestingly, a
clear correlation between the ability of cultured cells to
produce large amounts of IFN-a in response to viral stimu-
lation and the appearance of CD41HLA-DR1IL-3Ra11
Figure 4. Proliferative potential of pro-DC2, pre-DC2, and CD3411
progenitor cells. Freshly sorted CD3411CD45RA2, CD3411
CD45RA1, pro-DC2, and pre-DC2 were cultured for a total of 5 d with
GM-CSF, IL-3, SCF, and FLT3 ligand. [3H]Thymidine was added to the
cultures 8 h before incorporation was analyzed. (A) [3H]Thymidine up-
take of pro-DC2 and pre-DC2. (B) [3H]Thymidine uptake of
CD3411CD45RA2 and CD3411CD45RA1 cells. Uptake is calculated
as counts per minute.
Figure 5. Generation of IFN-a–producing cells from CD3411
CD45RA2 cells with FLT3 ligand or SCF. Sorted CD3411CD45RA2
cells were cultured with one of the following cytokines: IL-3, IL-7, SCF,
FLT3 ligand (FLT3-L), GM-CSF, or G-CSF. After 11 and 25 d of cul-
ture, equal numbers of cells were stimulated with HSV-1 for 24 h and
IFN-a (pg/ml) in the supernatants analyzed by ELISA.1791 Blom et al.
CD45RA1CD11c2 cells in culture with FLT3 ligand was
evidenced (Fig. 6, A and C).
To directly prove that the IL-3Ra11HLA-DR1 cells
generated from CD3411CD45RA2 early progenitor cells
with FLT3 ligand were pre-DC2/IPCs, FLT3 ligand–cul-
tured cells were separated into IL-3Ra11HLA-DR1 and
IL-3RalowHLA-DR1 populations by cell sorting. Stimula-
tion of sorted cells with HSV-1 for 24 h revealed that the
IL-3Ra11HLA-DR1 produced the larger amount of IFN-a
(50,238 pg/ml), which was seven times more than pro-
duced by the IL-3RalowHLA-DR1 (7,125 pg/ml; Fig. 7).
Notably, the amount of IFN-a produced by these in vitro
Figure 6. Kinetic analysis on
the ability of FLT3 ligand to
generate pre-DC2/IPCs from
CD3411CD45RA2 cells. Sorted
CD3411CD45RA2 cells were
cultured for a period up till 57 d
with FLT3 ligand. Every 5 d,
cells were harvested and ana-
lyzed. (A) Equal numbers of cells
were stimulated with HSV-1 (10
PFU/cell) for 24 h. The amount
of IFN-a (pg/ml) produced in
the supernatants was measured
by ELISA. (B) Phenotypical
analysis by flow cytometry after
staining with CD11c-FITC, IL-
3Ra–PE, and HLA-DR–Cy-
Chrome. Shaded histograms
show the IL-3Ra expression af-
ter electronic gating on HLA-
DR1CD11c2 cells. Open histo-
grams represent staining with an
isotype control antibody. (C)
Graphical representation of the
percentages of IL-3Ra11 cells
gated in B.
Figure 7. Phenotype and
IFN-a production of IL-
3Ra11HLA-DR1 cells. (A)
CD3411CD45RA2 cells cul-
tured for 30 d in FLT3 ligand
were analyzed by flow cytomet-
ric analysis after staining with ei-
ther CD11c-FITC, IL-3Ra–PE,
and HLA-DR–CyChrome or
HLA-DR–FITC, IL-3Ra–PE,
and CD4-CyChrome or
CD45RA-CyChrome. Shaded
histograms show the CD4,
CD11c, and CD45RA expres-
sion after electronic gating on
IL-3Ra11HLA-DR1 cells.
Open histograms represent stain-
ing with an isotype control anti-
body. (B) CD3411CD45RA2
cells cultured for 30 d in FLT3
ligand were stained with HLA-
DR–FITC and IL-3Ra–PE an-
tibodies. IL-3Ra11HLA-DR1
and IL-3RalowHLA-DR1 sub-
sets were sorted and stimulated
with HSV-1 for 24 h. IFN-a
(pg/ml) was measured in the su-
pernatants by ELISA.1792 Generation of IPCs from Stem Cells
generated cells is comparable to that produced by freshly
isolated IPCs from fetal liver (Table I).
These data indicate that pre-DC2/IPCs were generated
from CD3411CD45RA2 early hematopoietic progenitor
cells in culture with FLT3 ligand.
Other Hematopoietic Cytokines Do Not Promote the
FLT3 Ligand–induced Generation of Pre-DC2/IPCs from
CD3411CD45RA2 Early Progenitor Cells. To determine
if other cytokines could enhance the activity of FLT3
ligand to induce the generation of pre-DC2/IPCs,
CD3411CD45RA2 early hematopoietic progenitor cells
were cultured with FLT3 ligand with each of the following
cytokines: GM-CSF, G-CSF, IL-3, IL-7, and SCF. Al-
though G-CSF, and to a lesser extend GM-CSF and SCF,
enhanced the cellular expansion of CD3411CD45RA2
cells after 25 d of culture (Fig. 8 A), none of the cytokines
tested promoted the generation of pre-DC2/IPCs induced
by FLT3 ligand as determined by the capacity of IFN-a/b
production or by the pre-DC2/IPC phenotype (CD41
HLA-DR1IL-3Ra11CD45RA1CD11c2; Fig. 8, B and
C). Moreover, the tested cytokines, in particular IL-3, in-
hibited the generation of pre-DC2/IPCs induced by FLT3
ligand.
Discussion
The evolutionary pressure to fight numerous types of
microorganisms has endowed us with the development of
not only the sophisticated adaptive immune system, includ-
ing T and B lymphocytes, but also the divine innate im-
mune system. Whereas neutrophils and macrophages are
dedicated to eat and kill various bacterias, the eosinophils,
basophils, and mast cells have evolved to kill parasites. The
robust production of IFN-a/b of pre-DC2/IPCs in re-
sponse to viral stimulation suggests that pre-DC2/IPCs
represent a new member cell type of the hematopoietic
family and an effector cell type of the innate immune sys-
tem against antiviral infection.
Hematopoietic stem cells develop into committed effec-
tor cells depending on their microenvironment, which
provides them with the necessary stimuli. This develop-
ment is a multistep process that requires the orchestrated
availability of cytokines and chemokines in order for the
cells to proliferate, differentiate, and migrate accurately.
This study suggests a developmental pathway of pre-DC2/
IPCs from CD3411CD45RA2 early progenitors, to
CD3411CD45RA1 late progenitors, to CD341
CD45RA11IL-3Ra11CD41HLA-DR1CD11c2 pro-
Figure 8. Proliferation, IFN-
a–producing capacity, and phe-
notype of CD3411CD45RA2
cells cultured with FLT3 ligand
(FLT3-L) together with other
cytokines. CD3411CD45RA2
cells were cultured for 28 d and
analyzed. (A) The cell number
expansion of the different cul-
tures was calculated after count-
ing the live cells by trypan blue
exclusion. (B) Percentages of
IL-3Ra11HLA-DR1CD11c2 cells. Cultured cells were analyzed by flow cytometric analysis after staining with a combination of antibodies including
CD11c-FITC, IL-3Ra–PE, and HLA-DR–CyChrome. (C) 20,000 cells of each culture condition were stimulated with HSV-1 for 24 h and the
amount of IFN-a measured by ELISA.
Figure 9. Schematic representation of pre-DC2/IPC
development from CD3411 early progenitor cells.1793 Blom et al.
DC2, and finally to CD342CD45RA1IL-3Ra11CD41
HLA-DR1CD11c2 pre-DC2/IPCs (Fig. 9). This differen-
tiation pathway may provide a basis to study further the
function and development of pre-DC2 in normal and dis-
ease states. For example, it was recently reported that both
G-CSF and FLT3 ligand treatment of healthy donors in-
creased pre-DC2 numbers in the peripheral blood. This
study provides a model to study the effects of both cyto-
kines on the different developmental stages of pre-DC2 in
vivo. Furthermore, it has been reported that there is a pro-
gressive loss of the IFN-a/b–producing capacity of periph-
eral blood cells in response to viral stimulation in patients
with hairy cell leukemia, steroid treatment, idiopathic CD4
lymphopenia, and HIV (for a review, see reference 51). It
will be interesting to determine the stage where pre-DC2
development and function is disturbed in these patients in
order to anticipate clinical treatment.
This study also demonstrated the generation of pre-
DC2/IPCs in vitro from CD3411CD45RA2 early he-
matopoietic progenitor cells with FLT3 ligand. The gener-
ated cells not only had the capacity to produce huge
amounts of IFN-a/b in response to viral stimulation, but
also displayed a typical pre-DC2/IPC phenotype of
CD41IL-3Ra11CD45RA1HLADR1CD11c2. Notably,
the finding that neither pro-DC2 nor pre-DC2 could sur-
vive and proliferate in culture with FLT3 ligand over a
2-wk culture period indicates that the presence of pre-
DC2/IPCs was due to their differentiation from
CD3411CD45RA2 early progenitor cells, and not the
selective expansion of contaminating pro-DC2s or pre-
DC2s. Injection of FLT3 ligand was previously shown to
dramatically increase the numbers of both myeloid and
lymphoid DCs in blood and lymphoid tissues of mice (46,
52). A recent study by Pulendran et al. (45) showed that
FLT3 ligand treatment also increased the number of both
CD11c1 myeloid DCs and CD41IL-3Ra11CD11c2 pre-
DC2/IPCs in the peripheral blood of human donors.
These findings, together with this study, suggest that FLT3
ligand directly induces the differentiation of a proportion of
CD3411CD45RA2 early progenitor cells into pre-DC2/
IPCs. Whether FLT3 ligand promotes the migration of
pre-DC2 generated in bone marrow into the blood circu-
lation remains unknown. Two recent studies showed that
in G-CSF–treated patients or stem cell donors, the number
of pre-DC2 in blood was increased fivefold, whereas the
number of CD11c1 DCs was not affected (10, 45).
Our current finding that G-CSF was unable to induce
CD3411CD45RA2 early progenitor cells to differentiate
into pre-DC2/IPCs suggests that unlike FLT3 ligand,
G-CSF did not support differentiation of early hematopoi-
etic progenitor cells into pre-DC2/IPCs, but may promote
the migration of pre-DC2 into peripheral blood.
IFN-a/b has been widely used in treating patients with
viral hepatitis (53). Potentially, combination therapy of
IFN-a/b and FLT3 ligand or G-CSF can be used to in-
crease the number of pre-DC2/IPCs to treat patients with
chronic viral infection. Several studies suggest that in HIV-
infected patients, there is a progressive loss of the ability of
blood leukocytes to produce IFN-a/b in response to vi-
ral infections (54–56). Pre-DC2/IPCs express CD4 and
chemokine receptors CXCR4 and CCR5 (Kanzler, H., V.
Soumelis, and Y.-J. Liu, unpublished observation), which
are the receptors allowing HIV entry (57, 58). We have re-
cently observed that there is a dramatic decrease in pre-
DC2/IPC numbers in HIV-infected patients with AIDS,
in particular in AIDS patients with complication of infec-
tions and of Kaposi sarcoma (Soumelis, V., and Y.-J. Liu,
unpublished observation). Although it remains to be estab-
lished whether pre-DC2/IPCs are infected by HIV viruses,
FLT3 ligand together with the therapies preventing HIV
infection may be beneficial for patients to ultimately elimi-
nate viruses.
In conclusion, this study has mapped the pathways and
identified the cytokine regulation of pre-DC2/IPC devel-
opment from early hematopoietic stem cells in humans.
The pre-DC2/IPC developmental pathway may provide a
basis for monitoring pre-DC2/IPC numbers and develop-
ment in patients with tumors, autoimmune diseases, and
infectious diseases. FLT3 ligand and G-CSF may have the
potential to be used to stimulate the generation and mobili-
zation of pre-DC2/IPCs in patients who are fighting
against cancers and infectious diseases.
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